Cash-starved biotech companies in Korea are hoping to capitalize on changes to the listing rules for the Korean stock market introduced earlier this year to go public
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Louët, S. Korean biotechs seize opportunity to list on public markets. Nat Biotechnol 23, 1189–1190 (2005). https://doi.org/10.1038/nbt1005-1189
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1005-1189
This article is cited by
-
Hwang scandal hits Korean biotech hard
Nature (2006)
-
Erratum: Korean biotechs seize opportunity to list on public markets
Nature Biotechnology (2006)